Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Three Amendments On Comparative Effectiveness Research Fail During Finance Committee Markup

This article was originally published in The Pink Sheet Daily

Executive Summary

Chairman Baucus' attempt to find middle ground on one amendment is met with a hardline stance from Sen. Kyl, leading to the amendment's ultimate demise.

You may also be interested in...



PCORI Repeal Rhetoric Has Declined In Congress – Wilensky

During the run-up to the passing of the Affordable Care Act, the Patient-Centered Outcomes Research Institute was the target of much Republican criticism. But based on her interactions with congressional members, Project HOPE’s Gail Wilensky says there’s no desire now on Capitol Hill to end the institute’s activities.

PCORI’s Slow Start On Comparative Research May Protect It From Political Heat

The Patient-Centered Outcomes Research Institute’s slow ramp-up to being in a position to fund comparative research projects may actually help it survive a heated political environment in an election year.

Who’s Who On The Joint Select Committee On Deficit Reduction

The Budget Control Act created a 12-member bicameral panel charged with finding at least $1.2 trillion to cut from federal spending. The top Democrat and top Republican in each chamber of Congress appointed three members to serve on the joint committee. The Committee needs to make its legislative proposal by Thanksgiving, with only a simple majority needed to send the fiscal package to both chambers for approval. President Obama would then have to sign the bill by Jan. 15, 2012. A failure to accomplish this will trigger automatic spending cuts across all government programs as defined by the BCA (“Beware The Debt Deal’s Spending Cut Trigger: Medicare Part D and B Provider Pay Would Drop,” “The Pink Sheet” DAILY, Aug. 2, 2011). Health care related issues are expected to be a significant part of the discussions within the committee, including Medicaid-level rebates for drugs used by dual eligibles in the Medicare Part D program.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS070062

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel